{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:28:29Z","timestamp":1793842109633,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Korean Ministry of Science and ICT","id":[{"id":"https:\/\/ror.org\/01wpjm123","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cell and gene therapies hold great promise for treating monogenic disorders, yet their preclinical evaluation remains limited by the lack of scalable, human-specific models. Here we establish a patient-derived teratoma xenograft platform as a proof-of-concept system to evaluate ex vivo and in vivo therapeutic strategies for Duchenne muscular dystrophy (DMD). Teratomas generated from DMD patient-derived induced pluripotent stem cells contained mesodermal derivatives, including skeletal muscle-like tissue, enabling assessment of dystrophin restoration after therapeutic intervention. For ex vivo cell therapy, myogenic progenitors derived from adenine base editor-corrected induced pluripotent stem cells were transplanted into DMD teratomas, resulting in partial restoration of shorter dystrophin isoforms but not reproducible recovery of full-length Dp427m. For in vivo gene editing, local delivery of adenine base editor mRNA encapsulated in lipid nanoparticles induced dose-dependent editing and restoration of shorter dystrophin isoforms, including Dp71. Full-length, muscle-specific Dp427m was detected only in a subset of sequentially matured secondary teratomas with enriched muscle differentiation, indicating that myogenic maturation is a critical determinant of this therapeutic readout. Together, these findings support patient-derived DMD teratomas as an exploratory humanized platform for evaluating patient-specific gene correction and dystrophin isoform restoration, while highlighting the need for further optimization to reproducibly model full-length Dp427m recovery.<\/jats:p>","DOI":"10.1038\/s12276-026-01854-5","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:02:41Z","timestamp":1790812961000},"page":"3370-3381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-derived teratomas as a humanized platform for dystrophin restoration by ex vivo cell therapy and in vivo base editing"],"prefix":"10.1038","volume":"58","author":[{"given":"Mihn Jeong","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Bin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7432-8994","authenticated-orcid":false,"given":"Yuna","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Chan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Kyun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Gwi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SungHwan","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-8473","authenticated-orcid":false,"given":"Hyukjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9277-2662","authenticated-orcid":false,"given":"Hyuk-Jin","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"1854_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19505-2","volume":"11","author":"K Bulaklak","year":"2020","unstructured":"Bulaklak, K. & Gersbach, C. A. The once and future gene therapy. Nat. Commun. 11, 5820 (2020).","journal-title":"Nat. Commun."},{"key":"1854_CR2","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1016\/j.ymthe.2023.11.001","volume":"31","author":"D Chancellor","year":"2023","unstructured":"Chancellor, D., Barrett, D., Nguyen-Jatkoe, L., Millington, S. & Eckhardt, F. The state of cell and gene therapy in 2023. Mol. Ther. 31, 3376\u20133388 (2023).","journal-title":"Mol. Ther."},{"key":"1854_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"J-H Wang","year":"2024","unstructured":"Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L. & Gao, G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct. Target. Ther. 9, 78 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1854_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","volume":"22","author":"G Ferrari","year":"2021","unstructured":"Ferrari, G., Thrasher, A. J. & Aiuti, A. Gene therapy using haematopoietic stem and progenitor cells. Nat. Rev. Genet. 22, 216\u2013234 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"1854_CR5","doi-asserted-by":"crossref","unstructured":"Ebens, C. L. Targeting challenging RDEB skin wounds with gene therapy. Lancet 406, 106\u2013108 (2025).","DOI":"10.1016\/S0140-6736(25)01154-7"},{"key":"1854_CR6","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.ymthe.2025.05.006","volume":"33","author":"D Barrett","year":"2025","unstructured":"Barrett, D. & Digaudio, D. The landscape of cell and gene therapy today. Mol. Ther. 33, 2316\u20132323 (2025).","journal-title":"Mol. Ther."},{"key":"1854_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13287-023-03394-5","volume":"14","author":"J-C Park","year":"2023","unstructured":"Park, J.-C. et al. Gene editing with \u2018pencil\u2019 rather than \u2018scissors\u2019 in human pluripotent stem cells. Stem Cell Res. Ther. 14, 164 (2023).","journal-title":"Stem Cell Res. Ther."},{"key":"1854_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41392-024-01809-0","volume":"9","author":"J Cerneckis","year":"2024","unstructured":"Cerneckis, J., Cai, H. & Shi, Y. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Signal Transduct. Target. Ther. 9, 112 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1854_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan, D., Goemans, N., Takeda, S. I., Mercuri, E. & Aartsma-Rus, A. Duchenne muscular dystrophy. Nat. Rev. Dis. Primers 7, 13 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1854_CR10","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1172\/JCI142031","volume":"130","author":"S Biressi","year":"2020","unstructured":"Biressi, S., Filareto, A. & Rando, T. A. Stem cell therapy for muscular dystrophies. J. Clin. Invest. 130, 5652\u20135664 (2020).","journal-title":"J. Clin. Invest."},{"key":"1854_CR11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nprot.2015.057","volume":"10","author":"SM Maffioletti","year":"2015","unstructured":"Maffioletti, S. M. et al. Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells. Nat. Protoc. 10, 941\u2013958 (2015).","journal-title":"Nat. Protoc."},{"key":"1854_CR12","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/nprot.2016.110","volume":"11","author":"J Chal","year":"2016","unstructured":"Chal, J. et al. Generation of human muscle fibers and satellite-like cells from human pluripotent stem cells in vitro. Nat. Protoc. 11, 1833\u20131850 (2016).","journal-title":"Nat. Protoc."},{"key":"1854_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.stem.2018.06.010","volume":"23","author":"SS-K Chan","year":"2018","unstructured":"Chan, S. S.-K. et al. Skeletal muscle stem cells from PSC-derived teratomas have functional regenerative capacity. Cell Stem Cell 23, 74\u201385 (2018).","journal-title":"Cell Stem Cell"},{"key":"1854_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/cells12030362","volume":"12","author":"N Xie","year":"2023","unstructured":"Xie, N., Chu, S. N., Schultz, C. B. & Chan, S. S. Efficient muscle regeneration by human PSC-derived CD82+ ERBB3+ NGFR+ skeletal myogenic progenitors. Cells 12, 362 (2023).","journal-title":"Cells"},{"key":"1854_CR15","doi-asserted-by":"crossref","unstructured":"Azzag, K. et al. Preclinical quality, safety, and efficacy of a CGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophies. Mol. Ther. 33, 5099\u20135117 (2025).","DOI":"10.1016\/j.ymthe.2025.07.007"},{"key":"1854_CR16","doi-asserted-by":"publisher","first-page":"13714","DOI":"10.1073\/pnas.240335297","volume":"97","author":"B Wang","year":"2000","unstructured":"Wang, B., Li, J. & Xiao, X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl Acad. Sci. USA. 97, 13714\u201313719 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1854_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","volume":"362","author":"L Amoasii","year":"2018","unstructured":"Amoasii, L. et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science 362, 86\u201391 (2018).","journal-title":"Science"},{"key":"1854_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403\u2013407 (2016).","journal-title":"Science"},{"key":"1854_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23996-y","volume":"12","author":"L Xu","year":"2021","unstructured":"Xu, L. et al. Efficient precise in vivo base editing in adult dystrophic mice. Nat. Commun. 12, 3719 (2021).","journal-title":"Nat. Commun."},{"key":"1854_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50340-x","volume":"15","author":"J Lin","year":"2024","unstructured":"Lin, J. et al. Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model. Nat. Commun. 15, 5927 (2024).","journal-title":"Nat. Commun."},{"key":"1854_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg4910","volume":"7","author":"F Chemello","year":"2021","unstructured":"Chemello, F. et al. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci. Adv. 7, eabg4910 (2021).","journal-title":"Sci. Adv."},{"key":"1854_CR22","doi-asserted-by":"crossref","unstructured":"Qiu, H. et al. Efficient exon skipping by base-editor-mediated abrogation of exonic splicing enhancers. Cell Rep. 42, 113340 (2023).","DOI":"10.1016\/j.celrep.2023.113340"},{"key":"1854_CR23","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","volume":"81","author":"G Bulfield","year":"1984","unstructured":"Bulfield, G., Siller, W., Wight, P. & Moore, K. J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl Acad. Sci. USA. 81, 1189\u20131192 (1984).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1854_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-018-0045-4","volume":"3","author":"N Yucel","year":"2018","unstructured":"Yucel, N., Chang, A. C., Day, J. W., Rosenthal, N. & Blau, H. M. Humanizing the mdx mouse model of DMD: the long and the short of it. npj Regen. Med. 3, 4 (2018).","journal-title":"npj Regen. Med."},{"key":"1854_CR25","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.omtn.2022.07.024","volume":"29","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR\u2013Cas9 therapeutic gene editing. Mol. Ther. Nucleic Acids 29, 525\u2013537 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1854_CR26","doi-asserted-by":"crossref","unstructured":"Durbacz, M. Z. et al. Optimized genomic editing of a common Duchenne muscular dystrophy mutation in patient-derived muscle cells and a new humanized mouse model. Mol. Ther. Nucleic Acids 36, 102569 (2025).","DOI":"10.1016\/j.omtn.2025.102569"},{"key":"1854_CR27","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.ymthe.2021.09.003","volume":"29","author":"A Pickar-Oliver","year":"2021","unstructured":"Pickar-Oliver, A. et al. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy. Mol. Ther. 29, 3243\u20133257 (2021).","journal-title":"Mol. Ther."},{"key":"1854_CR28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.15283\/ijsc22171","volume":"16","author":"J-C Park","year":"2023","unstructured":"Park, J.-C., Kim, K.-T., Jang, H.-K. & Cha, H.-J. Transition substitution of desired bases in human pluripotent stem cells with base editors: a step-by-step guide. Int. J. Stem Cells 16, 234\u2013243 (2023).","journal-title":"Int. J. Stem Cells"},{"key":"1854_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48111-9","volume":"15","author":"J-C Park","year":"2024","unstructured":"Park, J.-C. et al. Enhancing genome editing in hPSCs through dual inhibition of DNA damage response and repair pathways. Nat. Commun. 15, 4002 (2024).","journal-title":"Nat. Commun."},{"key":"1854_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41587-022-01533-6","volume":"41","author":"ME Neugebauer","year":"2023","unstructured":"Neugebauer, M. E. et al. Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity. Nat. Biotechnol. 41, 673\u2013685 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1854_CR31","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","volume":"19","author":"EM Porto","year":"2020","unstructured":"Porto, E. M., Komor, A. C., Slaymaker, I. M. & Yeo, G. W. Base editing: advances and therapeutic opportunities. Nat. Rev. Drug Discov. 19, 839\u2013859 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1854_CR32","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/s41587-023-01994-3","volume":"42","author":"Y-L Xiao","year":"2024","unstructured":"Xiao, Y.-L., Wu, Y. & Tang, W. An adenine base editor variant expands context compatibility. Nat. Biotechnol. 42, 1442\u20131453 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1854_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0022-510X(89)90223-2","volume":"94","author":"LV Nicholson","year":"1989","unstructured":"Nicholson, L. V. et al. Dystrophin in skeletal muscle I. Western blot analysis using a monoclonal antibody. J. Neurol. Sci. 94, 125\u2013136 (1989).","journal-title":"J. Neurol. Sci."},{"key":"1854_CR34","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/S0002-9440(10)65354-0","volume":"154","author":"LV Anderson","year":"1999","unstructured":"Anderson, L. V. & Davison, K. Multiplex western blotting system for the analysis of muscular dystrophy proteins. Am. J. Pathol. 154, 1017\u20131022 (1999).","journal-title":"Am. J. Pathol."},{"key":"1854_CR35","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.cell.2020.10.018","volume":"183","author":"D McDonald","year":"2020","unstructured":"McDonald, D. et al. Defining the teratoma as a model for multi-lineage human development. Cell 183, 1402\u20131419 (2020).","journal-title":"Cell"},{"key":"1854_CR36","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1158\/0008-5472.CAN-05-3627","volume":"66","author":"EA Sausville","year":"2006","unstructured":"Sausville, E. A. & Burger, A. M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 66, 3351\u20133354 (2006).","journal-title":"Cancer Res."},{"key":"1854_CR37","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan, D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol. Ther. 31, 3123\u20133126 (2023).","journal-title":"Mol. Ther."},{"key":"1854_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/hum.2022.29198.bfs","volume":"33","author":"A Philippidis","year":"2022","unstructured":"Philippidis, A. After patient death, FDA places hold on Pfizer Duchenne muscular dystrophy gene therapy trial. Hum. Gene Ther. 33, 111\u2013115 (2022).","journal-title":"Hum. Gene Ther."},{"key":"1854_CR39","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek, A. et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 389, 1203\u20131210 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1854_CR40","doi-asserted-by":"crossref","unstructured":"Lek, A. et al. Meeting Report: 2023 Muscular Dystrophy Association Summit on \u2018Safety and Challenges in Gene Therapy of Neuromuscular Diseases\u2019. (SAGE, 2024).","DOI":"10.3233\/JND-240002"},{"key":"1854_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","volume":"4","author":"JM Levy","year":"2020","unstructured":"Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97\u2013110 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"1854_CR42","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Karik\u00f3, K. & T\u00fcreci, \u00d6 mRNA-based therapeutics\u2014developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1854_CR43","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"PS Kowalski","year":"2019","unstructured":"Kowalski, P. S., Rudra, A., Miao, L. & Anderson, D. G. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol. Ther. 27, 710\u2013728 (2019).","journal-title":"Mol. Ther."},{"key":"1854_CR44","doi-asserted-by":"publisher","first-page":"14490","DOI":"10.1074\/jbc.R114.548255","volume":"289","author":"O Novikova","year":"2014","unstructured":"Novikova, O., Topilina, N. & Belfort, M. Enigmatic distribution, evolution, and function of inteins. J. Biol. Chem. 289, 14490\u201314497 (2014).","journal-title":"J. Biol. Chem."},{"key":"1854_CR45","doi-asserted-by":"publisher","first-page":"e1008982","DOI":"10.1371\/journal.pcbi.1008982","volume":"17","author":"A Karollus","year":"2021","unstructured":"Karollus, A., Avsec, \u017d & Gagneur, J. Predicting mean ribosome load for 5\u2032UTR of any length using deep learning. PLoS Comput. Biol. 17, e1008982 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"1854_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-022-02674-2","volume":"23","author":"DE Andreev","year":"2022","unstructured":"Andreev, D. E. et al. Non-AUG translation initiation in mammals. Genome Biol. 23, 111 (2022).","journal-title":"Genome Biol."},{"key":"1854_CR47","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/d41573-022-00124-z","volume":"21","author":"K Kingwell","year":"2022","unstructured":"Kingwell, K. Base editors hit the clinic. Nat. Rev. Drug Discov. 21, 545\u2013547 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1854_CR48","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.ymthe.2022.02.003","volume":"30","author":"NE Bengtsson","year":"2022","unstructured":"Bengtsson, N. E. et al. Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model. Mol. Ther. 30, 2176\u20132185 (2022).","journal-title":"Mol. Ther."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01854-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01854-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01854-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:04:54Z","timestamp":1793840694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01854-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1854"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01854-5","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}